Hologic, Inc. (NASDAQ:HOLX) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 9,708,883 shares, a growth of 21.4% from the January 12th total of 7,998,980 shares. Based on an average daily volume of 2,710,198 shares, the days-to-cover ratio is presently 3.6 days. Approximately 3.5% of the shares of the company are short sold.

A number of research analysts recently issued reports on the company. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Evercore ISI assumed coverage on Hologic in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $50.00 price objective on shares of Hologic in a research report on Thursday, February 1st. Stifel Nicolaus lowered Hologic from a “buy” rating to a “hold” rating and reduced their price objective for the company from $45.00 to $42.00 in a research report on Friday. Finally, Cowen upgraded Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective for the company in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Hologic has a consensus rating of “Buy” and a consensus target price of $48.36.

Shares of Hologic (HOLX) opened at $37.75 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. The firm has a market capitalization of $10,438.97, a price-to-earnings ratio of 9.96, a price-to-earnings-growth ratio of 1.76 and a beta of 0.77. Hologic has a 12 month low of $35.33 and a 12 month high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to the consensus estimate of $785.80 million. Hologic had a return on equity of 20.75% and a net margin of 34.53%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.52 EPS. equities research analysts expect that Hologic will post 2.25 earnings per share for the current fiscal year.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.79% of the company’s stock.

A number of institutional investors have recently made changes to their positions in HOLX. Koch Industries Inc. raised its stake in shares of Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after buying an additional 1,142,138 shares in the last quarter. Chevy Chase Trust Holdings Inc. raised its stake in shares of Hologic by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock worth $8,975,000 after buying an additional 3,391 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Hologic by 15.5% in the 3rd quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock worth $10,458,000 after buying an additional 38,283 shares in the last quarter. Cipher Capital LP raised its stake in shares of Hologic by 57.9% in the 3rd quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after buying an additional 43,146 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Hologic by 66.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,487 shares of the medical equipment provider’s stock worth $458,000 after buying an additional 4,984 shares in the last quarter. 92.77% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Short Interest in Hologic, Inc. (HOLX) Increases By 21.4%” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://theolympiareport.com/2018/02/12/short-interest-in-hologic-inc-holx-increases-by-21-4.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.